Proteins

2021 Report on TGF Beta Receptor Type 2 Drugs in Development - Featuring Auxagen, InteRNA Technologies and Velvio Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 22, 2021
Health, Pharmaceutical, Branches of biology, Proteins, Biology, TGF beta receptors, Signal transduction, TGF beta receptor 2, Growth factors, Transforming growth factor beta, Transforming growth factor, TGF beta signaling pathway, TGF beta receptor 1

The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 7 molecules.
  • TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene.
  • It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects.

2021 Insights on Islet Amyloid Polypeptide Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Branches of biology, Amyloidosis, Proteins, Peptide hormones, Organ systems, Anti-diabetic drugs, Diabetes, Amylin, Endocrine system, Amyloid, IAPP, Insulin

The "Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules.
  • The latest report Islet Amyloid Polypeptide - Drugs in Development, 2021, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone.

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer

Retrieved on: 
Thursday, June 17, 2021
Science, Biotechnology, Research, Pharmaceutical, Publishing, Oncology, Health, Communications, Branches of biology, Proteins, Biology, Post-translational modification, Apoptosis, Organelles, Proteasome, Ubiquitin

Jian Jin and Yue Xiong, co-founders of Cullgen, have published a review of targeted protein degradation technology as well as a comprehensive summary of degraders in development for the treatment of cancer in the prestigious journal, Nature Reviews Cancer.

Key Points: 
  • Jian Jin and Yue Xiong, co-founders of Cullgen, have published a review of targeted protein degradation technology as well as a comprehensive summary of degraders in development for the treatment of cancer in the prestigious journal, Nature Reviews Cancer.
  • The article reviews the history and mechanism of targeted protein degradation, the ubiquitin-proteasome system, and the key principles required for design of heterobifunctional small-molecule degraders.
  • The publication also contains an in-depth review of the current state and challenges associated with the use of common E3 ligands.
  • Jin and Xiong have positioned Cullgen as one of the leading companies in this revolution of drug discovery.

Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials

Retrieved on: 
Thursday, June 17, 2021
Research, Hospitals, Clinical trials, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Membrane proteins, Proteins, Programmed cell death, Apoptosis, Oncogenes, Bcl-2 family, MCL1, Bcl-2

Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.

Key Points: 
  • Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.
  • MCL1 is a member of the Bcl-2 family, normally acting as a brake on the apoptosis pathway.
  • In many human cancers, the Mcl-1 gene is highly amplified, shifting the balance from pro- to anti-apoptotic signals and promoting cancer cell survival and tumor formation.
  • The MCL1 program is one of several programs pursued by the Center for Development of Therapeutics (CDoT) at the Broad Institute.

Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting

Retrieved on: 
Tuesday, June 15, 2021
Health, Other Health, Radiology, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Amyloidosis, Branches of biology, Proteins, Amyloid, Transthyretin, Proteopathy, Cardiac amyloidosis, AT-01 Pan-Amyloid Diagnostic, AT-02 PAR Therapeutic, AT-03 PAR Therapeutic, AT-04 PAR Therapeutic, Systemic Amyloidosis, Attralus, AT-01 PAN-AMYLOID DIAGNOSTIC, AT-02 PAR THERAPEUTIC, AT-03 PAR THERAPEUTIC, AT-04 PAR THERAPEUTIC, SYSTEMIC AMYLOIDOSIS, ATTRALUS

An oral presentation and posters described results from a clinical study evaluating AT-01 (124I-p5+14), a novel, radiolabeled, synthetic amyloid-targeting peptide designed for imaging systemic amyloid deposits.

Key Points: 
  • An oral presentation and posters described results from a clinical study evaluating AT-01 (124I-p5+14), a novel, radiolabeled, synthetic amyloid-targeting peptide designed for imaging systemic amyloid deposits.
  • Currently, a definitive diagnosis of systemic amyloidosis is often made following histological evaluation of a tissue biopsy, said Dr. Wall.
  • In addition, this imaging modality may provide further clinical information to help improve patient management and disease understanding.
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.

Prothena to Participate in JMP Securities Life Sciences Conference on June 16

Retrieved on: 
Thursday, June 10, 2021
Amyloidosis, Branches of biology, Proteins, Biology, Amyloid, Familial amyloid polyneuropathy, Transthyretin, Alzheimer's disease, AL amyloidosis

Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

Key Points: 
  • Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
  • Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics, built on protein dysregulation expertise, with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases.
  • Prothenas pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimers disease, Parkinsons disease and a number of other neurodegenerative diseases.
  • For more information, please visit the Companys website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Proteins, Tumor suppressor genes, Apoptosis, P53, Programmed cell death, Bert Vogelstein, Mdm2

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Monday, June 7, 2021
Proteins, Branches of biology, Multiple myeloma, Gamma secretase, Protein domains, Orphan drugs, Serum B-cell maturation antigen

Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells.

Key Points: 
  • Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells.
  • Our goal is to meaningfully improve clinical outcomes for patients with multiple myeloma and we look forward to generating clinical data using nirogacestat in combination with BCMA-directed therapies across modalities.
  • Seagen and SpringWorks will also form a joint development committee to manage the clinical study, which is expected to commence in the second half of 2021.
  • Nirogacestats ability to enhance the activity of BCMA-directed therapies has been observed in preclinical models of multiple myeloma.

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Amyloidosis, Branches of biology, Proteins, Anatomy, Neurological disorders, Protein folding, Histopathology, Structural proteins, Familial amyloid polyneuropathy, Transthyretin, NTLA, Amyloid

The presentation will include interim data from the ongoing dose-escalation portion of Intellias Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).

Key Points: 
  • The presentation will include interim data from the ongoing dose-escalation portion of Intellias Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).
  • Following safety assessment and dose optimization, Intellia intends to further evaluate NTLA-2001 in a broader population of people with ATTR amyloidosis, including those with cardiomyopathy.
  • Intellia will host a live webcast on Monday, June 28, 2021 at 8:00 a.m. E.T.
  • Intellias global Phase 1 trial is an open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Nestin, Proteins, American Society of Clinical Oncology, Branches of biology, Medicine, Cancer, CAN-3110, Candel Therapeutics, CAN-3110, CANDEL THERAPEUTICS

The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • As of the data cutoff date of April 21, 2021:
    30 patients were evaluable for safety.
  • Based on these data, we are excited to advance this innovative agent into further clinical trials."
  • Nestin is highly expressed in glioma cells and other tumor tissue but is absent in the healthy adult brain.